Literature DB >> 21876172

Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.

Joshua B Parsons1, Matthew W Frank, Chitra Subramanian, Panatda Saenkham, Charles O Rock.   

Abstract

The rationale for the pursuit of bacterial type 2 fatty acid synthesis (FASII) as a target for antibacterial drug discovery in Gram-positive organisms is being debated vigorously based on their ability to incorporate extracellular fatty acids. The regulation of FASII by extracellular fatty acids was examined in Staphylococcus aureus and Streptococcus pneumoniae, representing two important groups of pathogens. Both bacteria use the same enzymatic tool kit for the conversion of extracellular fatty acids to acyl-acyl carrier protein, elongation, and incorporation into phospholipids. Exogenous fatty acids completely replace the endogenous fatty acids in S. pneumoniae but support only 50% of phospholipid synthesis in S. aureus. Fatty acids overcame FASII inhibition in S. pneumoniae but not in S. aureus. Extracellular fatty acids strongly suppress malonyl-CoA levels in S. pneumoniae but not in S. aureus, showing a feedback regulatory system in S. pneumoniae that is absent in S. aureus. Fatty acids overcame either a biochemical or a genetic block at acetyl-CoA carboxylase (ACC) in S. aureus, confirming that regulation at the ACC step is the key difference between these two species. Bacteria that possess a stringent biochemical feedback inhibition of ACC and malonyl-CoA formation triggered by environmental fatty acids are able to circumvent FASII inhibition. However, if exogenous fatty acids do not suppress malonyl-CoA formation, FASII inhibitors remain effective in the presence of fatty acid supplements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21876172      PMCID: PMC3174620          DOI: 10.1073/pnas.1109208108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens.

Authors:  Ying-Jie Lu; Yong-Mei Zhang; Kimberly D Grimes; Jianjun Qi; Richard E Lee; Charles O Rock
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

2.  Novel bacterial acetyl coenzyme A carboxylase inhibitors with antibiotic efficacy in vivo.

Authors:  C Freiberg; J Pohlmann; P G Nell; R Endermann; J Schuhmacher; B Newton; M Otteneder; T Lampe; D Häbich; K Ziegelbauer
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis.

Authors:  R J Heath; Y T Yu; M A Shapiro; E Olson; C O Rock
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

4.  Triclosan targets lipid synthesis.

Authors:  L M McMurry; M Oethinger; S B Levy
Journal:  Nature       Date:  1998-08-06       Impact factor: 49.962

5.  Structural basis of lipid biosynthesis regulation in Gram-positive bacteria.

Authors:  Gustavo E Schujman; Marcelo Guerin; Alejandro Buschiazzo; Francis Schaeffer; Leticia I Llarrull; Georgina Reh; Alejandro J Vila; Pedro M Alzari; Diego de Mendoza
Journal:  EMBO J       Date:  2006-08-24       Impact factor: 11.598

6.  The soluble acyl-acyl carrier protein synthetase of Vibrio harveyi B392 is a member of the medium chain acyl-CoA synthetase family.

Authors:  Yanfang Jiang; Chi Ho Chan; John E Cronan
Journal:  Biochemistry       Date:  2006-08-22       Impact factor: 3.162

7.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties.

Authors:  Jun Wang; Stephen M Soisson; Katherine Young; Wesley Shoop; Srinivas Kodali; Andrew Galgoci; Ronald Painter; Gopalakrishnan Parthasarathy; Yui S Tang; Richard Cummings; Sookhee Ha; Karen Dorso; Mary Motyl; Hiranthi Jayasuriya; John Ondeyka; Kithsiri Herath; Chaowei Zhang; Lorraine Hernandez; John Allocco; Angela Basilio; José R Tormo; Olga Genilloud; Francisca Vicente; Fernando Pelaez; Lawrence Colwell; Sang Ho Lee; Bruce Michael; Thomas Felcetto; Charles Gill; Lynn L Silver; Jeffery D Hermes; Ken Bartizal; John Barrett; Dennis Schmatz; Joseph W Becker; Doris Cully; Sheo B Singh
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

8.  Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.

Authors:  R J Heath; C O Rock
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

9.  Inhibition of beta-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli.

Authors:  R J Heath; C O Rock
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

10.  Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis.

Authors:  A Dessen; A Quémard; J S Blanchard; W R Jacobs; J C Sacchettini
Journal:  Science       Date:  1995-03-17       Impact factor: 47.728

View more
  97 in total

1.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

2.  A two-helix motif positions the lysophosphatidic acid acyltransferase active site for catalysis within the membrane bilayer.

Authors:  Rosanna M Robertson; Jiangwei Yao; Stefan Gajewski; Gyanendra Kumar; Erik W Martin; Charles O Rock; Stephen W White
Journal:  Nat Struct Mol Biol       Date:  2017-07-17       Impact factor: 15.369

3.  Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).

Authors:  Jiangwei Yao; John B Maxwell; Charles O Rock
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

4.  Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.

Authors:  Karine Gloux; Mélanie Guillemet; Charles Soler; Claire Morvan; David Halpern; Christine Pourcel; Hoang Vu Thien; Gilles Lamberet; Alexandra Gruss
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 5.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

6.  Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.

Authors:  Tina L Mistry; Lena Truong; Arun K Ghosh; Michael E Johnson; Shahila Mehboob
Journal:  ACS Infect Dis       Date:  2016-10-27       Impact factor: 5.084

7.  DNA Binding and Sensor Specificity of FarR, a Novel TetR Family Regulator Required for Induction of the Fatty Acid Efflux Pump FarE in Staphylococcus aureus.

Authors:  Heba Alnaseri; Robert C Kuiack; Katherine A Ferguson; James E T Schneider; David E Heinrichs; Martin J McGavin
Journal:  J Bacteriol       Date:  2019-01-11       Impact factor: 3.490

8.  Fatty acids regulate stress resistance and virulence factor production for Listeria monocytogenes.

Authors:  Yvonne Sun; Brian J Wilkinson; Theodore J Standiford; Henry T Akinbi; Mary X D O'Riordan
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

9.  Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus.

Authors:  Joshua B Parsons; Jiangwei Yao; Matthew W Frank; Pamela Jackson; Charles O Rock
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

10.  AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.

Authors:  Krishnamurthy Narasimha Rao; Anirudha Lakshminarasimhan; Sarah Joseph; Swathi U Lekshmi; Ming-Seong Lau; Mohammed Takhi; Kandepu Sreenivas; Sheila Nathan; Rohana Yusof; Noorsaadah Abd Rahman; Murali Ramachandra; Thomas Antony; Hosahalli Subramanya
Journal:  Protein Sci       Date:  2015-04-02       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.